Navigation Links
For Reducing Mortality, Current and Emerging Therapies Have No Advantage Over Carvedilol in the Treatment of Coronary Heart Disease (Stable Angina)
Date:4/20/2009

Percutaneous Coronary Intervention Will Retain Decision Resources' Clinical Gold Standard for Stable Angina, According to a New Report from Decision Resources

WALTHAM, Mass., April 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed cardiologists identify a therapy's effect on mortality as the attribute that most influences their prescribing decisions in coronary heart disease (stable angina). Clinical data and the opinions of interviewed thought leaders indicate that current and emerging therapies have no advantage in this attribute over carvedilol (GlaxoSmithKline's Coreg, generics), the sales-leading agent in the market.

The new report entitled Coronary Heart Disease (Stable Angina): To Gain Share, Emerging Therapies Must Not Only Control Symptoms but Also Reduce Mortality also finds that a therapy that reduces plaque volume more than Pfizer's Lipitor/Sortis/Tahor at 18 months would earn a 28 percent patient share in stable angina in the United States and a 37 percent patient share in Europe, according to surveyed U.S. and European cardiologists.

In 2008, Decision Resources' proprietary clinical gold standard for stable angina was percutaneous coronary intervention (PCI). Based on available data and expert opinion, PCI will retain gold-standard status for stable angina in 2012 as surveyed physicians believe it to be the most efficacious therapy for treating the symptoms of stable angina.

"Interestingly, surveyed physicians also indicate that Cardium Therapeutics' gene therapy Generx has great potential in treating stable angina," said Decision Resources Analyst Kate Sullivan, B.S. "However, experts we interviewed believe gene therapy is still at least 10 years away from becoming a viable therapeutic approach for the indication, which leaves PCI, over the next decade, as the most efficacious therapy for providing symptom relief to patients."

About the Report

Coronary Heart Disease (Stable Angina): To Gain Share, Emerging Therapies Must Not Only Control Symptoms but Also Reduce Mortality is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                         Decision Resources, Inc.
    Christopher Comfort                        Elizabeth Marshall
    781-296-2597                               781-296-2563
    ccomfort@dresources.com                    emarshall@dresources.com



'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Reducing Costs, Not Care: Medical Travel to New Zealand Can Help Alleviate Rising U.S. Healthcare Expenses for Insurers and Self-funded Employers
2. New Mexican health-care program successful at reducing crippling health care costs
3. Mexican health care program successful at reducing crippling health care costs
4. Angiogenesis inhibitor improves brain tumor survival by reducing edema
5. ADD-care -- A Natural, Homeopathic Alternative Reducing Symptoms Related to Attention Deficit Disorder
6. Employment Technologies Announces Pre-release of EASyView Virtual Interview System, Reducing Employer Time and Costs
7. Reducing suicidal behaviors among adolescents
8. Experts in Government, Public Health, Public Policy and Science Outline Blueprint for Reducing Death and Disease From Tobacco in the United States
9. Home Care Tips for Reducing the Risk of Childhood Hospitalizations Due to Asthma
10. The New Crystalens HD Gives Many Baby Boomers and Seniors an Opportunity to See Clearly at All Distances while Reducing or Eliminating the Need for Glasses
11. Effectiveness of Progesterone in Reducing Preterm Births May Be Altered by Genetic Predisposition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix ... of Emergency Medicine , an emergency medicine professional association, to support the organization's ... , The American Academy of Emergency Medicine, or AAEM, seeks to empower emergency ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Emergency rooms provide ... to find. Unfortunately, this can leave patients with dental emergencies at risk of losing ... now offering emergency dental care. , Common dental emergencies include:, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Jessica Barron, of ... is now accepting new dental patients and families in the North Metro Denver area. ... services from cleanings to cosmetic dentistry, and all in the most relaxing environment. , ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... organization, welcomes S.S. Nesbitt as the latest addition to its growing list of ... other locations throughout the Southeast, from Orlando to Huntsville and in between. , ...
(Date:2/10/2016)... ... , ... Armune BioScience signed a definitive agreement with ARCpoint ... across the country. Launched in April of 2015, Apifiny is the only cancer specific, ... order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... LONDON , February 10, 2016 A new report ... 2021 - states that the Alzheimer,s disease market will more than double ... 2021, at a Compound Annual Growth Rate (CAGR) of 11%. ... Italy , Spain , the UK, and ... prevalence during the forecast period. --> Canada , ...
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 ... viral gene therapy manufacturing, and Renova™ Therapeutics, a biopharmaceutical ... and other chronic diseases, have entered into a Manufacturing ... produce cGMP-grade RT-100 (Ad5.hAC6) Drug Product for use in ... --> This relationship will leverage Lonza,s ...
(Date:2/10/2016)... , Feb. 10, 2016 Immune Pharmaceuticals Inc. ... announced today that it has filed a patent application ... other cancers. --> --> ... by administration of Ceplene (histamine dihydrochloride) in combination with ... of predicting the efficacy of Ceplene and IL-2 therapy ...
Breaking Medicine Technology: